
Sign up to save your podcasts
Or


In this episode of Diagnosing Dx, Iām joined by ā Garreth Hippeā , Chief Commercial Officer at ā GenomOncologyā , a software company helping turn complex genomic data into faster, more actionable decisions in oncology.
Garreth has spent much of his career in clinical genomics, bioinformatics, and healthcare software, and in this conversation we explore how the field has evolved over the last 20 years, from far slower sequencing workflows to a point where whole genomes can now be analysed in clinically meaningful timeframes. We also unpack how GenomOncology is helping labs bring genomic reporting in-house, reduce turnaround times, ease pressure on molecular pathologists, and match patients to relevant clinical trials before those opportunities are missed.
A big part of the discussion focuses on AI, not as hype, but as a real force multiplier in healthcare software. Garreth shares how it is accelerating development, improving reporting workflows, and opening up new ways to work with clinical and omics data. We also discuss why genomics is still underused in parts of oncology, where adoption is heading next, and why whole genome sequencing could play a much bigger role in the future of cancer care.
Key takeaways:
š¹ How software is helping translate genomic complexity into clinical action
š¹ Why clinical trial matching remains such a critical challenge in oncology
š¹ Where AI could have the biggest impact across precision medicine
š¹ Why whole genome sequencing may define the future of cancer care
Chapters:
00:00 Introduction
01:56 Garreth Hippeās background in clinical genomics and software
03:04 What clinical genomics means: somatic vs germline testing
05:28 How software in genomics has evolved over the last 20 years
07:14 AI in healthcare and precision medicine
09:34 What GenomOncology does and where it fits in the oncology workflow
15:14 How AI is accelerating product development and lean growth
20:21 The core problems GenomOncology is solving in reporting and clinical trial matching
26:10 Company progress, product development, and commercial milestones
33:46 Adoption challenges in genomics and the future of whole genome sequencing
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
In this first episode of Diagnosing WDx, the new womenās health-focused sister series from Diagnosing Dx, Iām joined by Marra Francis, MD, board-certified OB-GYN, womenās health expert, and advisor to multiple early-stage diagnostics companies.
Recorded in the week of International Womenās Day, this conversation explores one of the biggest blind spots in healthcare: the historic and ongoing gap in womenās diagnostics.
Marra breaks down why women were excluded from clinical trials for decades, why many diagnostics and therapeutics still used today were originally studied in men, and why conditions like preeclampsia remain dangerously under-researched. We also explore the role of startups, investors, and AI in helping close the data gap and drive a new era of innovation in womenās health.
If Diagnosing Dx shines a light on the diagnostics industry, Diagnosing WDx shines a light on the women it has overlooked for far too long.
Key takeaways:
š¹ Why women were historically excluded from clinical research
š¹ How gaps in data still affect diagnostics and therapeutics today
š¹ Why preeclampsia and autoimmune disease expose major weaknesses in womenās health research
š¹ The investment gap holding back progress in womenās diagnostics
š¹ Where AI, startups, and new research models could help move the field forward
Chapters:
00:00 Introduction
01:02 Welcome to Diagnosing WDx
01:53 Marraās background and path into womenās health diagnostics
04:49 The real diagnostic gaps women face in clinical practice
08:05 Marraās work across womenās health startups and innovation
11:11 Consumer health, trust, and access to testing
17:13 The history of womenās exclusion from clinical trials
20:10 Preeclampsia, autoimmune disease, and the real-world impact of the data gap
25:41 Why progress in womenās health is still not moving fast enough
29:22 Diagnostics tested in men and what that means for women today
32:59 Can AI help close the womenās health data gap?
42:10 What needs to change next in womenās diagnostics
47:47 Why Diagnosing WDx matters
Guest:
Marra S. Francis
LinkedIn: https://www.linkedin.com/in/marrasfrancis/
Resources mentioned:
1. Womenās Health Initiative
2. MIT Catalyst Program
3. For You and Me (FYM)
4. Nobel Prize in Medicine and Physiology
Diagnosing WDx is a sister series from Diagnosing Dx, hosted by Elevra Consulting, spotlighting the gaps, opportunities, and innovations shaping the future of womenās diagnostics.
Learn more: https://elevraconsulting.com/
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, Iām joined by ā Tammy Crawfordā , Chief Executive Officer, and ā Holly Ahernā , Chief Scientific Officer at ā Aces Diagnosticsā , a company building what could become the first highly accurate test across all stages of Lyme disease.
We explore why early Lyme is so often missed, the myth of the bullseye rash, and the structural gaps in todayās testing pathway. Tammy and Holly explain how their personal experiences shaped Aces Diagnosticsā mission and how theyāre approaching the problem with a more rigorous, data-driven framework built for real-world adoption.
This conversation is a grounded look at what it takes to restore confidence in infectious disease diagnostics and why more reliable testing could transform both patient outcomes and healthcare economics.
Key takeaways:
š¹ Why current Lyme diagnostics frequently miss early-stage disease
š¹ How combining multiple biomarkers improves diagnostic accuracy
š¹ The role of machine learning in interpreting complex immune signatures
š¹ Why FDA approval is essential for trust, adoption, and scale
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, Iām joined by ā Spencer Priceā , Chief Executive Officer at ā OraLivaā , a company building an AI-powered precision diagnostic designed to transform oral cancer detection and shift the standard of care.
We explore Spencerās unconventional move from autonomous vehicles into diagnostics, why OraLiva built commercialisation and reimbursement strategy into the company from day one, and what it really takes to turn breakthrough science into a product that fits seamlessly into clinical workflows. Spencer shares how understanding the healthcare landscape early can shape smarter partnerships, stronger positioning, and long-term scalability.
This conversation is a grounded look at how diagnostics startups can balance innovation with practicality, building technology that not only works, but gets adopted and paid for.
Key takeaways:
š¹ Why reimbursement strategy needs to start at seed stage
š¹ How AI is accelerating preventative diagnostics in oral cancer
š¹ The importance of stakeholder engagement across the healthcare ecosystem
š¹ Why flexibility and optionality are critical in early-stage diagnostics companies
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, Iām joined by Jake Lesinski, Co-founder and CEO of Checktor Biosciences, an ETH Zurich spin-out building a CRISPR-based chemistry platform designed to upgrade existing diagnostic systems rather than replace them.
We explore why speed, decentralisation, and practical integration, not hype, will define the next wave of molecular diagnostics. Jake shares how Checktor is approaching CRISPR from a clinical and commercial perspective, why matching PCR-level performance matters, and how distribution strategy can make or break even the strongest science.
This conversation is a grounded look at how diagnostics companies can scale responsibly, partner intelligently, and deliver real value to patients and healthcare systems.
Key takeaways:
š¹ Why rapid, accurate diagnostics remain one of healthcareās biggest unmet needs
š¹ How CRISPR is finally finding its footing in real clinical workflows
š¹ Why upgrading existing diagnostic infrastructure beats starting from scratch
š¹ What founders need to understand about partnerships, validation, and scale
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, Iām joined by Zivjena Vucetic, Chief Medical Officer at Mission Bio, to explore what it really takes to turn breakthrough diagnostics science into tools that change clinical decisions.
With nearly two decades across oncology, neurology, infectious disease, and single-cell technologies, Zivjena shares a rare perspective on the messy middle of diagnostics, where great science often stalls before reaching patients.
We dive into why starting with a clinical decision (not the technology) matters, how single-cell multiomics can unlock new insight in complex diseases like AML, and why diagnostics companies must think like product builders to succeed.
This conversation cuts through the hype to focus on adoption, workflow, validation, and what actually drives impact in modern diagnostics.
Key takeaways
š¹ Why most diagnostics fail on product design and workflow, not science
š¹ How single-cell multiomics can reveal clinically meaningful insights in heterogeneous diseases
š¹ Why defining the clinical decision and target product profile early is critical
š¹ What it really takes to move diagnostics from discovery to standard of care
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, Iām joined by Unika Alexander, Co-Founder and CEO of The Proficient Lab, to unpack whatās really happening inside todayās diagnostic labs and why many are under more pressure than ever.
This conversation goes beyond hype to look at the operational reality of diagnostics ā from compliance and reimbursement challenges to why modern labs need better data visibility to scale sustainably.
Key takeaways
š¹ Why staffing shortages are one of the biggest operational risks facing labs today
š¹ How AI can simplify compliance, audits, and data management ā without adding complexity
š¹ Why data governance and traceability are critical as labs scale across sites
š¹ What diagnostic leaders need to understand about regulation, reimbursement, and efficiency
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, Iām joined by Rachel Zayas, CEO of AGED Diagnostics, a company tackling one of the most underdiagnosed and overlooked conditions in healthcare: liver disease.
Rachel shares what it really takes to build a diagnostics company from scratch in a high-friction clinical space, why liver disease is so difficult to detect early, and how systemic gaps in specialist access are leaving high-risk patients behind. We also explore the discipline, resilience, and hard lessons that shaped AGED Diagnosticsā mission to diagnose disease earlierābefore irreversible damage occurs.
This conversation is a grounded look at early diagnostics, healthcare bottlenecks, and the realities of building in an area where the need is massive, but the infrastructure is stretched thin.
Takeaways:
š¹ Why liver disease often goes undetected until itās too late
š¹ How non-specific symptoms and specialist shortages delay diagnosis
š¹ The lessons learned as a two-time Founding CEO in Diagnostics
š¹ What early diagnostics could change for high-risk patients
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, Iām joined by Harald Steltzer, CEO of OrisDX, a company tackling one of the most overlooked gaps in diagnostics: early detection of head and neck cancer. Harald shares his journey from biochemistry and genetics into startup leadership, and why dentistry may be one of the most overlooked frontlines for early cancer detection today. We explore how OrisDX is rethinking diagnostics to reduce clinical friction, improve patient outcomes, and tackle one of healthcareās hardest problems: reimbursement and adoption. This episode is a focused deep dive into purpose-driven diagnostics, smart go-to-market strategy, and what it really takes to launch a new clinical test in todayās healthcare system. Key takeaways: š¹ Why head and neck cancer remains under-detectedāand how dentistry can change thatš¹ The role of early detection, education, and digital health in improving outcomesš¹ How diagnostics founders should think about reimbursement from day oneš¹ What it takes to take a novel diagnostic from concept to clinical launch š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
In this episode of Diagnosing Dx, I sit down with FrĆ©dĆ©ric D. Sweeney, President & CEO of VedaBio, the company pioneering a completely new class of molecular diagnostics ā one that detects DNA and RNA without amplification while maintaining full clinical sensitivity in under 10 minutes.
We explore how this platform could transform urgent care, decentralised testing, and infectious disease workflows ā and why VedaBio believes the next leap in molecular diagnostics wonāt come from making PCR faster, but from removing amplification entirely.
FrĆ©dĆ©ric also opens up about the realities of transitioning from feasibility to product development, building the right team, navigating todayās funding climate, and why 2026 is shaping up to be a pivotal year for the company.
Takeaways:
š¹Why removing amplification could reshape point-of-care diagnostics
š¹How patient experience drives VedaBioās product vision
š¹The importance of strategic partnerships during early scaling
š¹What founders need to know about fundraising and team building in todayās diagnostics market
š Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.
From the publisher's feed